Fig. 3

Expression patterns of circulating miRs separate patients based on the response to dovitinib treatment. a Principal component analysis of the expression of six miRs before treatment (closed circles) and after treatment (open circles): patients 001, 002, 004, 005, 102, 103: 4 weeks; patients 101, 301: 8 weeks. The arrows indicate the before-to-after direction of the change. Patients that are separated by color code to indicate changes in tumor sizes after 8 weeks treatment (red = increase, green = decrease, grey = no change). b Cluster analysis of the miR expression changes after 4 or 8 weeks treatment with dovitinib. The dashed line indicates significant differences (Euclidian distance) between 3 patient groups. c Changes in six circulating miRs early after dovitinib treatment (4 weeks, except patient 101 and 103 at 8 weeks) based on tumor responses. The fold change in expression after treatment relative to U6 is indicated. Error bars = SEM, *p < 0.05; **p = 0.0032; ***p = 0.0006 by unpaired t-test. d Principal Component Analysis of the changes in expression of six miRs after dovitinib at multiple time points. The red circle includes patients with dovitinib resistant tumors. Patient 103 at 24 weeks is the exception in this group